Literature DB >> 15890918

Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity.

Surender Khurana1, Michael Kennedy, Lisa R King, Hana Golding.   

Abstract

CCR5 is the major coreceptor for human immunodeficiency virus (HIV) infection. The murine monoclonal antibody (MAb) 2D7, which recognizes a conformation-dependent epitope in the second extracellular loop of CCR5, is one of the most potent inhibitors of R5 virus cell entry. However, attempts to humanize 2D7 for in vivo human use have been unsuccessful so far. A filamentous phage library expressing random peptides was used to identify a peptide mimitope that is recognized by MAb 2D7. A synthetic peptide containing this sequence (2D7-2SK) bound to MAb 2D7 with high affinity and reversed its HIV type 1 (HIV-1) fusion inhibitory activity. The peptide contains sequence homologies to two distal regions of the second extracellular loop of human CCR5, both of which are required for MAb 2D7 binding. Rabbit anti-2D7-mimitope antibodies competed with MAb 2D7 for binding to the 2D7-2SK peptide in Biacore biosensor testing. Importantly, the rabbit anti-2D7-2SK antibodies bound to CCR5 on cells and specifically inhibited R5 (but not X4) envelope-mediated syncytium formation. These antibodies also neutralized infection of human peripheral blood mononuclear cells with R5 HIV isolates comparably to MAb 2D7. In summary, we have identified a novel peptide that closely mimics the MAb 2D7 epitope on CCR5. This peptide could be included as a potential vaccine candidate or to isolate 2D7-like human antibodies as entry inhibitors for R5 viruses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15890918      PMCID: PMC1112162          DOI: 10.1128/JVI.79.11.6791-6800.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

Review 1.  Co-receptor antagonists as HIV-1 entry inhibitors.

Authors:  Farida Shaheen; Ronald G Collman
Journal:  Curr Opin Infect Dis       Date:  2004-02       Impact factor: 4.915

2.  Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient.

Authors:  C Balotta; P Bagnarelli; M Violin; A L Ridolfo; D Zhou; A Berlusconi; S Corvasce; M Corbellino; M Clementi; M Clerici; M Moroni; M Galli
Journal:  AIDS       Date:  1997-08       Impact factor: 4.177

3.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.

Authors:  T Dragic; V Litwin; G P Allaway; S R Martin; Y Huang; K A Nagashima; C Cayanan; P J Maddon; R A Koup; J P Moore; W A Paxton
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

4.  Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection.

Authors:  R Liu; W A Paxton; S Choe; D Ceradini; S R Martin; R Horuk; M E MacDonald; H Stuhlmann; R A Koup; N R Landau
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

Review 5.  The beta-chemokines, HIV type 1 second receptors, and exposed uninfected persons.

Authors:  W A Paxton; T Dragic; R A Koup; J P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  1996-09-01       Impact factor: 2.205

6.  The genes encoding the human CC-chemokine receptors CC-CKR1 to CC-CKR5 (CMKBR1-CMKBR5) are clustered in the p21.3-p24 region of chromosome 3.

Authors:  M Samson; P Soularue; G Vassart; M Parmentier
Journal:  Genomics       Date:  1996-09-15       Impact factor: 5.736

7.  Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.

Authors:  Petra Mooij; Ivonne G Nieuwenhuis; Christiaan J Knoop; Robert W Doms; Willy M J M Bogers; Peter J F Ten Haaft; Henk Niphuis; Wim Koornstra; Kurt Bieler; Josef Köstler; Brør Morein; Aurelio Cafaro; Barbara Ensoli; Ralf Wagner; Jonathan L Heeney
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

8.  Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus.

Authors:  Bryce Chackerian; Lindsey Briglio; Paul S Albert; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

9.  Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1.

Authors:  P Lusso; F Cocchi; C Balotta; P D Markham; A Louie; P Farci; R Pal; R C Gallo; M S Reitz
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

10.  Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding.

Authors:  L Wu; G LaRosa; N Kassam; C J Gordon; H Heath; N Ruffing; H Chen; J Humblias; M Samson; M Parmentier; J P Moore; C R Mackay
Journal:  J Exp Med       Date:  1997-10-20       Impact factor: 14.307

View more
  14 in total

Review 1.  Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets.

Authors:  S Phogat; R T Wyatt; G B Karlsson Hedestam
Journal:  J Intern Med       Date:  2007-07       Impact factor: 8.989

2.  The isolation of novel phage display-derived human recombinant antibodies against CCR5, the major co-receptor of HIV.

Authors:  Moria Shimoni; Alon Herschhorn; Yelena Britan-Rosich; Moshe Kotler; Itai Benhar; Amnon Hizi
Journal:  Viral Immunol       Date:  2013-08       Impact factor: 2.257

3.  Recombinant human T-cell leukemia virus types 1 and 2 Tax proteins induce high levels of CC-chemokines and downregulate CCR5 in human peripheral blood mononuclear cells.

Authors:  Christy S Barrios; Muna Abuerreish; Michael D Lairmore; Laura Castillo; Chou-Zen Giam; Mark A Beilke
Journal:  Viral Immunol       Date:  2011-11-23       Impact factor: 2.257

4.  The second extracellular loop of CCR5 contains the dominant epitopes for highly potent anti-human immunodeficiency virus monoclonal antibodies.

Authors:  Jun Zhang; Eileen Rao; Marianna Dioszegi; Rama Kondru; Andre DeRosier; Eva Chan; Stephan Schwoerer; Nick Cammack; Michael Brandt; Surya Sankuratri; Changhua Ji
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

5.  Mapping Interaction Sites on Human Chemokine Receptors by Deep Mutational Scanning.

Authors:  Jeremiah D Heredia; Jihye Park; Riley J Brubaker; Steven K Szymanski; Kevin S Gill; Erik Procko
Journal:  J Immunol       Date:  2018-04-20       Impact factor: 5.422

6.  Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors.

Authors:  Maria Espirito-Santo; Quirina Santos-Costa; Marta Calado; Patrick Dorr; J Miguel Azevedo-Pereira
Journal:  AIDS Res Hum Retroviruses       Date:  2011-10-03       Impact factor: 2.205

7.  Direct measurement of thermal stability of expressed CCR5 and stabilization by small molecule ligands.

Authors:  Adam M Knepp; Amy Grunbeck; Sourabh Banerjee; Thomas P Sakmar; Thomas Huber
Journal:  Biochemistry       Date:  2010-12-30       Impact factor: 3.162

8.  Biophysical and structural investigation of bacterially expressed and engineered CCR5, a G protein-coupled receptor.

Authors:  Maciej Wiktor; Sébastien Morin; Hans-Jürgen Sass; Fabian Kebbel; Stephan Grzesiek
Journal:  J Biomol NMR       Date:  2012-12-11       Impact factor: 2.835

Review 9.  Phages and HIV-1: from display to interplay.

Authors:  Sylvie Delhalle; Jean-Claude Schmit; Andy Chevigné
Journal:  Int J Mol Sci       Date:  2012-04-13       Impact factor: 6.208

10.  Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness.

Authors:  Sai V Vemula; Yadvinder S Ahi; Anne-Marie Swaim; Jacqueline M Katz; Ruben Donis; Suryaprakash Sambhara; Suresh K Mittal
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.